Angela J. Oh

Scaffold-based discovery of indeglitazar, a PPAR pan-active anti-diabetic agent

Dean R. Artis, Jack J. Lin, Chao Zhang et al. · Proceedings of the National Academy of Sciences · 2008 · 146 citations · Full text

Metabolic Syndrome, Medicinal Chemistry, Biochemistry +15

Design and pharmacology of a highly specific dual FMS and KIT kinase inhibitor

Chao Zhang, Prabha N. Ibrahim, Jiazhong Zhang et al. · Proceedings of the National Academy of Sciences · 2013 · 95 citations · Full text

Drug Target, Specific Dual Fms, Immunology +23

Discovery of Clinical Candidate (1<i>R</i>,4<i>r</i>)-4-((<i>R</i>)-2-((<i>S</i>)-6-Fluoro-5<i>H</i>-imidazo[5,1-<i>a</i>]isoindol-5-yl)-1-hydroxyethyl)cyclohexan-1-ol (Navoximod), a Potent and Selective Inhibitor of Indoleamine 2,3-Dioxygenase 1

Sanjeev Kumar, Jesse P. Waldo, Firoz A. Jaipuri et al. · Journal of Medicinal Chemistry · 2019 · 82 citations · Full text

Quantitative Determination of Protein–Ligand Affinity by Size Exclusion Chromatography Directly Coupled to High-Resolution Native Mass Spectrometry

Chengfeng Ren, Aaron O. Bailey, Erica C. VanderPorten et al. · Analytical Chemistry · 2018 · 62 citations

Pupillometry evaluation of melanopsin retinal ganglion cell function and sleep-wake activity in pre-symptomatic Alzheimer’s disease

Angela J. Oh, Giulia Amore, William Sultan et al. · PLoS ONE · 2019 · 45 citations · Full text